Myelodysplastic syndrome
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
... Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patients; moreover, the incidence of high risk MDS is pro- portionally greater in ...
8
An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia
... Background: Myelodysplastic syndrome (MDS) is rare in the pediatric age group and it may be associated with inheritable bone marrow failure (BMF) such as Fanconi anemia ...
6
Range Determination of Antigen Expression in Myeloid, Erythroid and Lymphoid Cell Lineages among Patients with Myelodysplastic Syndrome
... 12. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing ...
8
Is Iron Chelation Therapy Useful in Persons with Myelodysplastic Syndrome Receive?
... Iron overload in myelodysplastic syndrome (MDS) results from multiple RBC-transfusions and inappropriate increased iron absoption associated with ineffective erythropoiesis. Data from hereditary ...
5
Extensive myocardial infiltration by hemopoietic precursors in a patient with myelodysplastic syndrome
... with myelodysplastic syn- dromes [22,23], more frequently in patients with chronic myelomonocytic leukemia compared to RAEB and refrac- tory cytopenia with multilineage dysplasia ...with myelodysplastic ...
7
Characterisation of Cell Population Data and Angiogenesis in Myelodysplastic Syndrome
... Myelodysplastic syndrome (MDS) is a clonal disorder, which affects the pluripotent hematopoietic stem cells. Hence the abnormal development is reflected in all the major cells lineages namely the erythroid, ...
128
<p>Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease</p>
... Keywords: myelodysplastic syndrome, acute myeloid leukemia, Decitabine, transplantation conditioning, graft versus host disease, allogeneic hematopoietic stem cell transplantation.. Intr[r] ...
9
Original Article GDF11 is increased in patients with myelodysplastic syndrome
... Abstract: Objective: To explore the role of growth differentiation factor 11 (GDF11) in patients with myelodysplastic syndrome (MDS) in erythropoietic functions. Methods: The serum GDF11 in MDS patients was ...
8
Aberrant Methylation-Mediated Suppression of APAF1 in Myelodysplastic Syndrome
... Background: Myelodysplastic syndromes (MDSs) include a diverse group of clonal bone marrow disorders characterized by ineffective hematopoiesis and ...in myelodysplastic syndrome (MDS) ...
7
DETECTION OF JAK2 MUTATION IN CASES OF MYELODYSPLASTIC SYNDROME
... The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include clonal myeloid neoplasms that overlap the MDS and MPN categories and at the time of initial diagnosis exhibit some clinical, laboratory, or ...
8
Novel combinations to improve hematopoiesis in myelodysplastic syndrome
... Myelodysplastic syndrome (MDS) is a group of clonal hematologic disorders characterized by the abnormal and ineffective hematopoiesis with an increased risk of acute myeloid leukemia (AML) transformation ...
5
Eight-ball hyphema after laser iridotomy in a patient with undiagnosed hypocellular myelodysplastic syndrome
... Introduction: We report a rare case of unexpected gross hyphema in the right eye (OD) and eight-ball hyphema in the left eye (OS) from a bilateral laser iridotomy in an acute primary angle-closure patient. We also ...
5
Response to treatment with 5-azacitidine in myelodysplastic syndrome in a small mexican population
... with myelodysplastic syndrome has demonstrated efficacy in previous clinical studies, evaluated by the normalization of hematopoiesis, decreased transfusion requirement, increase in disease-free survival ...
5
Antiretroviral activity of 5 azacytidine during treatment of a HTLV 1 positive myelodysplastic syndrome with autoimmune manifestations
... In our case, myelodysplastic syndrome and autoim- mune phenomena were also accompanied by a positive PCR for HTLV-1. HTLV-1 has been implicated in the pathogenesis of ATLL and tropical spastic paraparesis. ...
5
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
... non-deletion(5q) myelodysplastic syndrome (MDS) at one of two doses (2000 mg or 2500 mg/day) in combination with 10 mg of lenalidomide on days 1 – 21 of a 28-day ...
8
Donor-Cell Origin High-Risk Myelodysplastic Syndrome Synchronous with an Intracranial Meningioma-Like Tumor, 8 Years after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
... high-risk myelodysplastic syndrome (MDS) of donor-cells origin, both diagnosed simultaneously, 8 years after an allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic lymphocytic ...
6
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
... Abstract: The goals of treating older patients with myelodysplastic syndrome (MDS) are different than for younger patients. Few elderly patients are able to pursue an allogeneic stem cell transplant for ...
9
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials
... Background: Aberrant DNA methylation has been identified as a key molecular event regulating the pathogenesis of myelodysplastic syndromes (MDS); myeloid neoplasms with an inherent risk of transformation to acute ...
9
Myelodysplastic syndrome (MDS) associated with EBV infection in a pediatric patient
... Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and a high propensity to transform to acute myeloid leukemia (AML). These are common hematological diseases in the elderly but are ...
7
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
... In an attempt to identify the subset of lower-risk patients likely to benefit from therapy with ezatiostat, we exam- ined pre-therapy marrow cells from ezatiostat-treated MDS patients by[r] ...
8